- Published on
KembaraXtra- Medicine – Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) is a malignancy of hematopoietic progenitor cells that normally mature into granulocytes. More broadly, AML sits within the acute nonlymphocytic leukemia (ANLL) spectrum, which includes leukemias arising from myeloid stem cells and precursors of granulocytes, monocytes, erythrocytes, and megakaryocytes, distinguishing them from leukemias of lymphocytic origin. AML is characterized by maturation failure of myeloid progenitors, accumulation of immature blasts, and bone marrow failure leading to varying degrees of neutropenia, thrombocytopenia, and anemia. Acute promyelocytic leukemia (APL/APML) is a distinct AML syndrome with very different treatment implications and must be recognized urgently due to its high risk of catastrophic bleeding.
Synonyms include acute nonlymphocytic leukemia (ANLL), acute myelogenous leukemia, and AML. ICD-10-CM codes include C92.00–C92.02 (acute myeloblastic leukemia categories), C92.60–C92.62 (AML with 11q23 abnormality categories), C92.90–C92.92 (myeloid leukemia unspecified categories), C92.A0–C92.A2 (AML with multilineage dysplasia categories), and C92.Z0–C92.Z2 (other myeloid leukemia categories).
AML incidence rises with age. In adults aged 20–55 years, incidence is approximately 1–3 per 100,000 persons/year, increasing to 11–20 per 100,000 persons/year in those aged 65–80 years, representing about a tenfold increase. The median age at diagnosis is ~68 years (SEER 2015–2019). Overall annual incidence is about 4 per 100,000 persons/year. Males are affected slightly more than females, and individuals of European ancestry slightly more than those of African ancestry.
Clinical presentation is commonly due to bone marrow failure and/or hyperleukocytosis. Cytopenia-related findings include bleeding from thrombocytopenia, fatigue and shortness of breath from anemia, and infections from neutropenia. Systemic symptoms may include fatigue, fever (usually infectious, less commonly tumor-related), and sometimes bone pain (noted as more common in ALL than AML). Physical examination often reflects cytopenias (e.g., pallor, bruising/petechiae), while lymphadenopathy and hepatosplenomegaly are rare, and the exam may otherwise be normal.
A critical “don’t miss” scenario is hyperleukocytic leukemia, typically with WBC >100,000/µL, which can cause leukostasis and ischemic complications. These include retinal hemorrhage and visual symptoms (blurred vision, diplopia), intracranial bleeding or neurologic deficits (headache, confusion, delirium, paralysis), respiratory compromise (dyspnea, tachypnea, hypoxia from pulmonary involvement), and organ ischemia (stroke, myocardial infarction, priapism). Another high-risk complication is disseminated intravascular coagulation (DIC), especially prominent in APL, though DIC can occur in other acute leukemias (notably acute monocytic leukemia). AML may rarely present as extramedullary disease such as leukemia cutis, blastic plasmacytoid dendritic cell neoplasm (BPDCN), or granulocytic sarcoma. Gingival hypertrophy and tissue/organ involvement are more typical of monocytic leukemia.
Etiology and risk contributors include environmental exposures (with benzene best documented), organic solvents, cigarette smoking, and obesity (best documented in women). Hereditary predisposition syndromes include bone marrow failure syndromes (Fanconi anemia, Bloom syndrome, Shwachman-Diamond syndrome, Diamond-Blackfan anemia), genetic disorders (e.g., Down syndrome), and familial AML syndromes (e.g., DDX41, RUNX1, GATA2 mutations), among others. Therapy-related AML (t-AML) accounts for roughly 10%–20% of cases and classically occurs after exposure to alkylating agents (latency 5–7 years, often associated with chromosome 5/7 abnormalities and/or TP53) or topoisomerase II inhibitors (latency 1–3 years, often associated with 11q23/KMT2A (MLL) rearrangements). Radiation exposure can contribute, and AML may also arise after antecedent hematologic disorders (myelodysplasia, myeloproliferative disorders, aplastic anemia). Clonal hematopoiesis of indeterminate potential (CHIP) is increasingly recognized as a precursor state that may predispose to AML years later.
The differential diagnosis includes other disorders with circulating blasts or blast-like cells: AML/ALL, myelodysplasia (which can show up to 20% circulating blasts; ≥20% blasts meets AML criteria), primary myelofibrosis, chronic myeloid leukemia, blastoid mantle cell lymphoma, prolymphocytic leukemia, BPDCN, and reactive atypical lymphocytes in EBV/CMV infections that may appear blast-like.
Diagnosis requires combined assessment of morphology, immunophenotyping, cytogenetics, and molecular testing. Initial evaluation includes CBC and peripheral smear, recognizing that morphology can suggest lineage but flow cytometry and/or cytochemistry are needed for confirmation. Auer rods support myeloid lineage. LDH is commonly elevated. Baseline labs assess organ function (creatinine, liver enzymes) and screen for spontaneous tumor lysis syndrome (uric acid, potassium, phosphate, calcium). Vitamin B12 and folate can be low due to rapid turnover and may require replacement. Coagulation studies (PT, aPTT, fibrinogen) are essential to evaluate for DIC, which is always present in APL and can occur in other acute leukemias. HLA typing supports transplant planning and platelet support.
Cytochemical stains may be rapidly available: myeloperoxidase (MPO) positivity supports myeloid origin and can be obtained quickly, while nonspecific esterase supports monocytic differentiation. Flow cytometry on blood and/or marrow typically confirms lineage and maturation stage and uses marker patterns such as precursor markers (CD34, CD117, CD13, CD133, HLA-DR), granulocytic markers (CD65, cytoplasmic MPO), monocytic markers (CD14, CD36, CD64), megakaryocytic markers (CD41, CD61), and erythroid markers (CD235, CD36). Cytogenetic studies (karyotype) are ideally performed on bone marrow but can be done on peripheral blood; FISH is commonly used as an adjunct. Next-generation sequencing / PCR panels detect prognostic and targetable mutations—commonly FLT3, NPM1, IDH1/IDH2, and CEBPA—and broader panels are increasingly used because of evolving prognostic frameworks and targeted therapy availability.
A formal AML diagnosis is established when blasts are ≥20% in the marrow or peripheral blood, unless AML-defining recurrent cytogenetic abnormalities are present—especially t(8;21), inv(16)/t(16;16), or t(15;17)—in which case AML can be diagnosed regardless of blast percentage. Risk stratification commonly follows genetic groupings: favorable-risk disease includes core-binding factor AML (e.g., t(8;21), inv(16)/t(16;16)) and certain normal-karyotype molecular profiles (e.g., mutated NPM1 without FLT3-ITD, or favorable CEBPA patterns), intermediate-risk includes several mixed molecular/cytogenetic patterns, and adverse-risk includes lesions such as inv(3)/t(3;3), t(6;9), KMT2A/MLL rearrangements, t(9;22), and RUNX1/ASXL1/TP53 mutations, as well as -5/del(5q), -7, abnl(17p), and complex karyotype.
Treatment is typically organized into urgent stabilization plus disease-directed therapy. Immediate priorities include correction of life-threatening complications (infection/sepsis risk in neutropenia, bleeding/DIC especially in APL, tumor lysis syndrome, and leukostasis/hyperleukocytosis). AML therapy generally includes induction to achieve remission (commonly “7+3”: daunorubicin for 3 days plus cytarabine continuous infusion for 7 days in many fit patients), followed by consolidation to prevent relapse (often intermediate/high-dose cytarabine in favorable-risk disease, and consideration of allogeneic stem cell transplant in intermediate/unfavorable-risk disease when appropriate). Hyperleukocytosis may require rapid cytoreduction (e.g., hydroxyurea and/or chemotherapy) and sometimes leukapheresis depending on clinical context. Tumor lysis syndrome prevention and management relies on vigorous hydration, close electrolyte monitoring, and uric-acid–lowering strategies as indicated.
A major “don’t miss” subtype is acute promyelocytic leukemia (APL/APML), associated with t(15;17) PML-RARA, which presents with high hemorrhagic risk due to DIC and requires immediate initiation of all-trans retinoic acid (ATRA) when suspected—often before full molecular confirmation—along with aggressive supportive transfusion strategies to maintain fibrinogen and platelet thresholds. Modern APL protocols (ATRA + arsenic trioxide for many risk groups, with intensified approaches in higher-risk cases) achieve very high cure rates, but early death from bleeding remains a key preventable risk.
Pearls and key considerations include that AML can be an emergency depending on presentation; evaluation should be rapid and coordinated with hematology and laboratory expertise. APL is a true medical emergency because early ATRA can rapidly improve coagulopathy and reduce fatal hemorrhage risk.
0 Comments
